SecBot SecBot
Insider Cluster (3 insiders) ·Filed Apr 1, 2026

RMD

RESMED INC
NEUTRAL
Impact 3/10
Horizonimmediate Processed7mo ago
Insider cluster: 3 insiders, $1.8M total
Actionable Insight • Neutral

This cluster reflects routine, planned selling, common after option vesting or under 10b5-1 plans, rather than a negative signal. No meaningful economic impact; monitor for sustained selling trends or changes in buying activity.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$222.19
T+0 close · Mar 31, 2026 · via day close
Latest settled
−9.85%
T+60 · $200.29
Vs SPY
−21.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 1 $222.19entry
  2. T+1 · 8mo ago +0.86%α +0.78% · $224.09
  3. T+5 · 7mo ago +2.62%α −1.14% · $228.02
  4. T+20 · 7mo ago −4.62%α −14.34% · $211.93
  5. T+60 · 5mo ago −9.85%α −21.11% · $200.29
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ResMed insiders sold $1.8M in shares over a 7-day period, led by CEO Michael Farrell's $1.13M open-market sale following the exercise of derivative securities. The total value represents 0.005% of ResMed's $33.6B market cap, indicating routine, non-material activity.

Key Financial Metrics

Direction
selling
Total Value
$1.8M
Insiders
3

Key Facts

  • CEO Michael Farrell sold 4,991 shares for $1.13M in an open-market transaction on 2026-04-07.
  • Farrell also exercised derivative securities totaling 9,982 shares (one tranche at $0, one at $146.34), a non-cash event.
  • Director Peter Farrell sold $450K and CFO Brett Sandercock sold $224K, both on 2026-04-01.
  • Total insider selling: $1.8M over 7 days, all by insiders with pre-arranged 10b5-1 plans likely.

Financial Impact

$1.8M in total open-market sales, representing 0.005% of $33.6B market cap

insider ownershipshare countsentiment

Risk Factors

  • Perception risk if media mischaracterizes CEO sale as lack of confidence
  • Potential for short-term sentiment pressure despite lack of fundamental concern

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RMD-1775749477250

Track record

19 reports on RMD

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +28.97% at T+60 after the Jun 1, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 9, 20267d ago 144 Neutral 2/10 Entry $234.11 Now $238.19 +1.74% settles Dec 9
  2. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  3. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $229.94 Now $238.19 +3.59% settles Nov 30
  4. Oct 16, 20264w ago Institutional Cluster Bearish 4/10 Entry $238.88 to $238.19 Now $238.19 +0.29% ▲ +0.29% −3.17% vs SPY
  5. Oct 7, 20265w ago 144 Neutral 3/10 Entry $226.73 to $240.51 Now $238.19 +5.05% ▲ +6.08% +11.37% vs SPY
  6. Oct 1, 20266w ago DEFA14A Neutral 2/10 Entry $218.89 to $229.94 Now $238.19 +8.82% ▲ +5.05% +6.86% vs SPY
  7. Oct 1, 20266w ago DEF 14A Neutral 4/10 Entry $218.89 to $252.83 Now $238.19 +8.82% ▲ +15.51% +17.31% vs SPY
  8. Oct 1, 20266w ago Press Release Neutral 1/10 Entry $218.89 Now $238.19 +8.82% No price data
  9. Sep 10, 20269w ago Insider Cluster Neutral 4/10 Entry $219.58 to $226.73 Now $238.19 +8.48% ▲ +3.26% +1.13% vs SPY
  10. Aug 11, 202613w ago Insider Cluster Neutral 2/10 Entry $224.84 to $219.95 Now $238.19 +5.94% ▼ −2.17% −1.12% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens Wed (11h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 9, 2026